Geode Capital Management LLC Has $4.28 Million Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Geode Capital Management LLC lifted its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 1.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,814,446 shares of the company’s stock after acquiring an additional 44,762 shares during the period. Geode Capital Management LLC owned approximately 2.24% of Atossa Therapeutics worth $4,278,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in ATOS. Bank of New York Mellon Corp grew its holdings in shares of Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the last quarter. XTX Topco Ltd raised its holdings in Atossa Therapeutics by 101.2% during the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock worth $75,000 after purchasing an additional 24,951 shares during the last quarter. State Street Corp boosted its position in Atossa Therapeutics by 4.2% during the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock valued at $2,633,000 after acquiring an additional 69,180 shares during the last quarter. Rhumbline Advisers acquired a new stake in Atossa Therapeutics during the 2nd quarter worth about $161,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Atossa Therapeutics during the 3rd quarter worth about $75,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Trading Up 5.2 %

NASDAQ:ATOS opened at $1.01 on Monday. The firm’s 50 day moving average is $1.22 and its 200 day moving average is $1.30. Atossa Therapeutics, Inc. has a 12 month low of $0.77 and a 12 month high of $2.31. The stock has a market capitalization of $127.06 million, a PE ratio of -4.59 and a beta of 1.26.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ATOS shares. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Atossa Therapeutics in a research report on Thursday, December 12th. Ascendiant Capital Markets lifted their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.